4 results about "Passive Immunotherapy" patented technology

The invention discloses a hybridoma cell strain capable of secreting a monoclonal antibody with bovine coronavirus neutralizing activity and application of the hybridoma cell strain, and belongs to the technical field of antibody drugs. The preservation number of the hybridoma cell strain is CCTCC (China Center For Type Culture Collection) NO: C2025147. The hybridoma cell strain can be used for preparing a monoclonal antibody with bovine coronavirus neutralizing activity, and the monoclonal antibody shows excellent neutralizing titer on bovine coronavirus and is subjected to cross-neutralization reaction with related sheep coronavirus (cpCoV). The monoclonal antibody obtained by the invention not only can be used for developing a high-sensitivity specific diagnostic reagent aiming at the BCoV, but also provides a new core biological material for developing a passive immunotherapy preparation with a potential broad-spectrum protection effect; the method has important application value in the aspects of coping with virus variation and improving the overall prevention and control capability of the coronavirus of the ruminant.

The invention relates to immunogenic compositions comprising a capsular polysaccharide (CP) from Streptococcus agalactiae, commonly referred to as group B streptococcus (GBS), conjugated to a carrier protein, and optionally including an aluminum-based adjuvant. The invention further relates to methods for inducing an immune response in subjects against GBS and / or for reducing or preventing invasive GBS disease in subjects using the compositions disclosed herein. The resulting antibodies can be used to treat or prevent GBS infection via passive immunotherapy.

The invention relates to immunogenic compositions comprising a capsular polysaccharide (CP) from Streptococcus agalactiae, commonly referred to as group B Streptococcus (GBS), conjugated to a carrier protein, and optionally including an aluminum-based adjuvant. The invention further relates to methods for inducing an immune response in subjects against GBS and / or for reducing or preventing invasive GBS disease in subjects using the compositions disclosed herein. The resulting antibodies can be used to treat or prevent GBS infection via passive immunotherapy.

The application discloses a Mycoplasma bovum LP586 protein, a polyclonal antibody thereof and application. The amino acid sequence of the LP586 protein is shown as SEQ ID NO. 1, the LP586 protein has high conservation, is positioned on the cell membrane surface of the Mycoplasma bovum, and has multiple biological functions such as specific adhesion to EBL cells, combination with extracellular matrix molecules and activation of plasminogen in the presence of tPA. The application further provides a high-titer specific polyclonal antibody prepared by immunization. The LP586 protein can be used as a key antigen for preparing a Mycoplasma bovum subunit vaccine, a diagnostic reagent or a therapeutic drug; and the polyclonal antibody thereof can be used for preparing a diagnostic reagent or a passive immunotherapy preparation. The application provides a brand-new high-efficiency target and product development basis for prevention and control of the Mycoplasma bovum disease.